Expression of prenylated Rab acceptor 1 domain family, member 2 (PRAF2) in neuroblastoma: Correlation with clinical features, cellular localization, and cerulenin-mediated apoptosis regulation

Clinical Cancer Research

Volumn 13, Issue 21, 2007, Pages 6312-6319

  Geerts, Dirk ^c   Wallick, Christopher J ^a   Koomoa, Dana Lynn T ^a   Koster, Jan ^c   Versteeg, Rogier ^c   Go, Ramon Christopher V ^a,b   Bachmann, André S ^a,b  

^a UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CERULENIN; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PRENYLATED RAB ACCEPTOR 1 DOMAIN FAMILY MEMBER 2; RAB PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL FEATURE; CONTROLLED STUDY; CYTOPLASM; ENZYME DEGRADATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; MICROARRAY ANALYSIS; MYCM GENE; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; STAINING;

APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; CERULENIN; CHILD, PRESCHOOL; ENDOSOMES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; INFANT, NEWBORN; MEMBRANE PROTEINS; MICROSCOPY, FLUORESCENCE; NEUROBLASTOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN STRUCTURE, TERTIARY; TISSUE DISTRIBUTION;

EID: 35948973569     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0829     Document Type: Article

References (27)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
2. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77.
3. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. Prog Clin Biol Res 1994;385:363-9.
4. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-79.
5. Shimada H, Chatten J, Newton WA, Jr., et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984;73:405-16.
6. Fo CS, Coleman CS, Wallick CJ, Vine AL, Bachmann AS. Genomic organization, expression profile, and characterization of the new protein PRA1 domain family, member 2( PRAF2). Gene 2006;371:154-65.
7. Schweneker M, Bachmann AS, Moelling K. JM4 is a four-transmembrane protein binding to the CCR5 receptor. FEBS Lett 2005;579:1751-8.
8. Bachmann AS, Duennebier FF, Mocz G. Genomic organization, characterization, and molecular 3D model of GDE1, a novel mammalian glycerophosphoinositol phosphodiesterase. Gene 2006;371:144-53.
9. Barrett T, Suzek TO, Troup DB, et al. NCBIGEO: mining millions of expression profiles-database and tools. Nucleic Acids Res 2005;33:D562-6.
10. Barrett T, Troup DB, Wilhite SE, et al. NCBI GEO: mining tens of millions of expression profiles-database and tools update. Nucleic Acids Res 2007;35:D760-5.
11. Cheng NC, Van Roy N, Chan A, et al. Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification. Oncogene 1995;10:291-7.
12. Wallick CJ, Gamper I, Thorne M, et al. Key role for p27Kip1, retinoblastoma protein Rb, and MYCN in polyamine inhibitor-induced G1 cell cycle arrest in MYCN-amplified human neuroblastoma cells. Oncogene 2005;24:5606-18.
13. Bewick V, Cheek L, Ball J. Statistics review 12: survival analysis. Crit Care 2004;8:389-94.
14. Sivars U, Aivazian D, Pfeffer S. Purification and properties of Yip3/PRA1 as a Rab GDI displacement factor. Methods Enzymol 2005;403:348-56.
15. Sivars U, Aivazian D, Pfeffer SR. Yip3 catalyses the dissociation of endosomal Rab-GDI complexes. Nature 2003;425:856-9.
16. Lin CI, Orlov I, Ruggiero AM, et al. Modulation of the neuronal glutamate transporter EAAC1 by the interacting protein GTRAP3-18. Nature 2001;410:84-8.
17. Heiligtag SJ, Bredehorst R, David KA. Key role of mitochondria in cerulenin-mediated apoptosis. Cell Death Differ 2002;9:1017-25.
18. Slade RF, Hunt DA, Pochet MM, Venema VJ, Hennigar RA. Characterization and inhibition of fatty acid synthase in pediatric tumor cell lines. Anticancer Res 2003;23:1235-43.
19. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006;66:5977-80.
20. Takamori S, Holt M, Stenius K, et al. Molecular anatomy of a trafficking organelle. Cell 2006;127:831-46.
21. Compton SL, Behrend EN. PRAF1: a Golgi complex transmembrane protein that interacts with viruses. Biochem Cell Biol 2 006;84:940-8.
22. Dirac-Svejstrup AB, Sumizawa T, Pfeffer SR. Identification of a GDI displacement factor that releases endosomal Rab GTPases from Rab-GDI. EMBO J 1997;16:465-72.
23. Chen H, Bai J, Ye J, et al. JWA as a functional molecule to regulate cancer cells migration via MAPK cascades and F-actin cytoskeleton. Cell Signal 2007;19:1315-27.
24. Huang S, Shen Q, Mao WG, et al. JWA, a novel signaling molecule, involved in the induction of differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 2006;341:440-50.
25. Huang S, Shen Q, Mao WG, et al. JWA, a novel signaling molecule, involved in all-trans retinoic acid induced differentiation of HL-60 cells. J Biomed Sci 2006;13:357-71.
26. Mao WG, Liu ZL, Chen R, Li AP, Zhou JW. JWA is required for the antiproliferative and pro-apoptotic effects of all-trans retinoic acid in Hela cells. Clin Exp Pharmacol Physiol 2006;33:816-24.
27. Shen Q, Tang WY, Li CP, et al. Functional variations in the JWA gene are associated with increased odds of leukemias. Leuk Res 2007;31:783-90.